Research ExplorerPublicationsSecond allogeneic transplantation for relapse of malignant d...

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT

Standard

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. / Ruutu, T; de Wreede, L C; van Biezen, A; Brand, R; Mohty, M; Dreger, P; Duarte, R; Peters, C; Garderet, L; Schönland, S; Gratwohl, A; Niederwieser, D; de Witte, T; Kröger, Nicolaus.

In: BONE MARROW TRANSPL, Vol. 50, No. 12, 12.2015, p. 1542-50.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ruutu, T, de Wreede, LC, van Biezen, A, Brand, R, Mohty, M, Dreger, P, Duarte, R, Peters, C, Garderet, L, Schönland, S, Gratwohl, A, Niederwieser, D, de Witte, T & Kröger, N 2015, 'Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT', BONE MARROW TRANSPL, vol. 50, no. 12, pp. 1542-50. https://doi.org/10.1038/bmt.2015.186

APA

Ruutu, T., de Wreede, L. C., van Biezen, A., Brand, R., Mohty, M., Dreger, P., Duarte, R., Peters, C., Garderet, L., Schönland, S., Gratwohl, A., Niederwieser, D., de Witte, T., & Kröger, N. (2015). Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. BONE MARROW TRANSPL, 50(12), 1542-50. https://doi.org/10.1038/bmt.2015.186

Vancouver

Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. BONE MARROW TRANSPL. 2015 Dec;50(12):1542-50. https://doi.org/10.1038/bmt.2015.186

Bibtex

@article{48bada7d37704857b64fa52faa5dd2aa,
title = "Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT",
abstract = "In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of second allogeneic SCT is often uncertain. In a retrospective analysis, 2632 second allogeneic transplantations carried out for a relapse after the first transplantation were analyzed to define indications and identify predictive factors. Fifteen percent of the patients remained relapse-free until 5 years after the second SCT. Patients with CML had a better survival than patients with other diseases. In a multivariate analysis, factors associated with better survival were low disease burden, longer remission duration after the first transplantation, longer interval between the transplantations, younger age, absence of grade II-IV acute GvHD or chronic GvHD after the first transplantation, and later year of transplantation. The European Society for Blood and Marrow Transplantation risk score predicted the outcome. Using the same donor as in the first transplantation vs another donor had no predictive value for survival. Sibling donor was a favorable predictive factor. In conclusion, second allogeneic SCT offers a reasonable option especially for young patients with a long remission after the first transplantation and a low disease burden. The present findings do not support the usefulness of changing the donor for the second transplantation.",
author = "T Ruutu and {de Wreede}, {L C} and {van Biezen}, A and R Brand and M Mohty and P Dreger and R Duarte and C Peters and L Garderet and S Sch{\"o}nland and A Gratwohl and D Niederwieser and {de Witte}, T and Nicolaus Kr{\"o}ger",
year = "2015",
month = dec,
doi = "10.1038/bmt.2015.186",
language = "English",
volume = "50",
pages = "1542--50",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT

AU - Ruutu, T

AU - de Wreede, L C

AU - van Biezen, A

AU - Brand, R

AU - Mohty, M

AU - Dreger, P

AU - Duarte, R

AU - Peters, C

AU - Garderet, L

AU - Schönland, S

AU - Gratwohl, A

AU - Niederwieser, D

AU - de Witte, T

AU - Kröger, Nicolaus

PY - 2015/12

Y1 - 2015/12

N2 - In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of second allogeneic SCT is often uncertain. In a retrospective analysis, 2632 second allogeneic transplantations carried out for a relapse after the first transplantation were analyzed to define indications and identify predictive factors. Fifteen percent of the patients remained relapse-free until 5 years after the second SCT. Patients with CML had a better survival than patients with other diseases. In a multivariate analysis, factors associated with better survival were low disease burden, longer remission duration after the first transplantation, longer interval between the transplantations, younger age, absence of grade II-IV acute GvHD or chronic GvHD after the first transplantation, and later year of transplantation. The European Society for Blood and Marrow Transplantation risk score predicted the outcome. Using the same donor as in the first transplantation vs another donor had no predictive value for survival. Sibling donor was a favorable predictive factor. In conclusion, second allogeneic SCT offers a reasonable option especially for young patients with a long remission after the first transplantation and a low disease burden. The present findings do not support the usefulness of changing the donor for the second transplantation.

AB - In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of second allogeneic SCT is often uncertain. In a retrospective analysis, 2632 second allogeneic transplantations carried out for a relapse after the first transplantation were analyzed to define indications and identify predictive factors. Fifteen percent of the patients remained relapse-free until 5 years after the second SCT. Patients with CML had a better survival than patients with other diseases. In a multivariate analysis, factors associated with better survival were low disease burden, longer remission duration after the first transplantation, longer interval between the transplantations, younger age, absence of grade II-IV acute GvHD or chronic GvHD after the first transplantation, and later year of transplantation. The European Society for Blood and Marrow Transplantation risk score predicted the outcome. Using the same donor as in the first transplantation vs another donor had no predictive value for survival. Sibling donor was a favorable predictive factor. In conclusion, second allogeneic SCT offers a reasonable option especially for young patients with a long remission after the first transplantation and a low disease burden. The present findings do not support the usefulness of changing the donor for the second transplantation.

U2 - 10.1038/bmt.2015.186

DO - 10.1038/bmt.2015.186

M3 - SCORING: Journal article

C2 - 26367221

VL - 50

SP - 1542

EP - 1550

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -